ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

NVTR Nuvectra Corporation

0.13
0.00 (0.00%)
14 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Nuvectra Corporation NASDAQ:NVTR NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.13 0.1304 0.15 0 01:00:00

Nuvectra to Report Second Quarter 2017 Financial Results on August 8, 2017

25/07/2017 9:01pm

GlobeNewswire Inc.


Nuvectra (NASDAQ:NVTR)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Nuvectra Charts.

Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the second quarter ended June 30, 2017 on Tuesday, August 8, 2017 after market close.

Nuvectra will hold a conference call on Tuesday, August 8, 2017 at 4:30pm ET to discuss the results. The dial in numbers are (844) 882-7830 for domestic callers and (574) 990-9704 for international callers. The conference ID is 58530044.  A live webcast of the conference call will be available on the investor relations section of the Company’s website at http://investors.nuvectramed.com/.

A replay of the call will be available starting on August 8, 2017 through August 15, 2017. To access the replay, dial (855) 859-2056 for domestic callers and (404) 537-3406 for international callers and enter access code 58530044. The webcast will be available in the investor relations section of the Company’s website for 90 days following the completion of the call.

About Nuvectra Corporation

NuvectraTM is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic intractable pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other indications such as sacral neuromodulation (SNM) for the treatment of overactive bladder, and deep brain stimulation (DBS) for the treatment of Parkinson’s Disease. In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at www.nuvectramed.com.

Company Contacts:		
Nuvectra Corporation		

Walter Berger, COO & CFO		
(214) 474-3102			
wberger@nuvectramed.com		
				
Jennifer Armstrong, Media Relations	
(214) 474-3110			
jarmstrong@nuvectramed.com	

Investor Contacts:
The Ruth Group		

Zack Kubow
(646) 536-7020		
zkubow@theruthgroup.com

Brian Johnston
(646) 536-7028
bjohnston@theruthgroup.com

1 Year Nuvectra Chart

1 Year Nuvectra Chart

1 Month Nuvectra Chart

1 Month Nuvectra Chart

Your Recent History

Delayed Upgrade Clock